Summary
Global Markets Direct’s, ‘Radiodermatitis - Pipeline Review, H1 2016’, provides an overview of the Radiodermatitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Radiodermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Radiodermatitis
- The report reviews pipeline therapeutics for Radiodermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Radiodermatitis therapeutics and enlists all their major and minor projects
- The report assesses Radiodermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Radiodermatitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Radiodermatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Radiodermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
ProCertus BioPharm Inc.
Reata Pharmaceuticals, Inc.
SK Chemicals Co., Ltd.
Vida Therapeutics Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Radiodermatitis Overview 6
Therapeutics Development 7
Pipeline Products for Radiodermatitis - Overview 7
Pipeline Products for Radiodermatitis - Comparative Analysis 8
Radiodermatitis - Therapeutics under Development by Companies 9
Radiodermatitis - Therapeutics under Investigation by Universities/Institutes 10
Radiodermatitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Radiodermatitis - Products under Development by Companies 13
Radiodermatitis - Products under Investigation by Universities/Institutes 14
Radiodermatitis - Companies Involved in Therapeutics Development 15
ProCertus BioPharm Inc. 15
Reata Pharmaceuticals, Inc. 16
SK Chemicals Co., Ltd. 17
Vida Therapeutics Inc. 18
Radiodermatitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
omaveloxolone - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PrC-210 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SKI-2162 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ST-266 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
VTI-1000 Series - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Radiodermatitis - Recent Pipeline Updates 37
Radiodermatitis - Dormant Projects 39
Radiodermatitis - Discontinued Products 40
Radiodermatitis - Product Development Milestones 41
Featured News & Press Releases 41
Jul 25, 2014: Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis 41
Apr 24, 2014: RTA 408 Lotion Demonstrates Favorable Safety and Pharmacodynamic Response in a Phase 1 Study 41
Apr 10, 2014: Preclinical Study of Reata's RTA 408 Demonstrates Role in Prevention and Treatment of Radiation Dermatitis 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Researcha 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44
List of Tables
Number of Products under Development for Radiodermatitis, H1 2016 7
Number of Products under Development for Radiodermatitis - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Radiodermatitis - Pipeline by ProCertus BioPharm Inc., H1 2016 15
Radiodermatitis - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 16
Radiodermatitis - Pipeline by SK Chemicals Co., Ltd., H1 2016 17
Radiodermatitis - Pipeline by Vida Therapeutics Inc., H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Radiodermatitis Therapeutics - Recent Pipeline Updates, H1 2016 37
Radiodermatitis - Dormant Projects, H1 2016 39
Radiodermatitis - Discontinued Products, H1 2016 40
List of Figures
Number of Products under Development for Radiodermatitis, H1 2016 7
Number of Products under Development for Radiodermatitis - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 20
Number of Products by Stage and Top 10 Targets, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 22
Number of Products by Stage and Mechanism of Actions, H1 2016 22
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Molecule Types, H1 2016 26
Number of Products by Stage and Top 10 Molecule Types, H1 2016 26
